Current and Potential Applications of Left Ventricular Assist Devices

Cianci, Pamela; Lonergan-Thomas, Helen; Slaughter, Mark S.; Silver, Marc A.

doi:10.1097/00005082-200301000-00003

Cited by 11 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main purpose of an LVAD is as a bridge to recovery, maintaining the normal cardiac output for patients in heart failure [1,2] while benefiting the cardiac recovery effect [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Computational analysis of the effect of the type of LVAD flow on coronary perfusion and ventricular afterload

et al. 2009

View full text Add to dashboard Cite

We developed a computational model to investigate the hemodynamic effects of a pulsatile left ventricular assist device (LVAD) on the cardiovascular system. The model consisted of 16 compartments for the cardiovascular system, including coronary circulation and LVAD, and autonomic nervous system control. A failed heart was modeled by decreasing the end-systolic elastance of the ventricle and blocking the mechanism controlling heart contractility. We assessed the physiological effect of the LVAD on the cardiovascular system for three types of LVAD flow: co-pulsation, counter-pulsation, and continuous flow modes. The results indicated that the pulsatile LVAD with counter-pulsation mode gave the most physiological coronary blood perfusion. In addition, the counter-pulsation mode resulted in a lower peak pressure of the left ventricle than the other modes, aiding cardiac recovery by reducing the ventricular afterload. In conclusion, these results indicate that, from the perspective of cardiovascular physiology, a pulsatile LVAD with counter-pulsation operation is a plausible alternative to the existing LVAD with continuous flow mode.

show abstract

Section: Introductionmentioning

confidence: 99%

Computational analysis of the effect of the type of LVAD flow on coronary perfusion and ventricular afterload

et al. 2009

View full text Add to dashboard Cite

show abstract

“…9 Furthermore, 41% of patients who received VADs in this trial died of sepsis-related complications. 21 Another study that looked at 55 LVADs as bridge to transplantation reported that 53% of patients developed clinical infections (drivelines, urine, sputum, or abscess cavities within the device). Another retrospective study that was conducted on 90 patients with LVAD confirmed the high rate (20%) of device-related infections.…”

Section: Infectionmentioning

confidence: 99%

Complications in Patients With Ventricular Assist Devices

Barnes

2008

Dimensions of Critical Care Nursing

View full text Add to dashboard Cite

Heart failure affects more than 5 million people in the United States. The treatments of this disease include medical therapy, heart transplantation, and the implantation of ventricular assist devices. These devices are used in patients who are no longer responsive to conservative medical treatment, who are not candidates for a heart transplantation (destination therapy), who are awaiting a heart transplantation (bridge to transplantation), and who have acute heart failure and whose myocardial function is expected to return to normal (bridge to recovery). Although this therapy improves the mortality and quality of life among patients with heart failure, the devices also carry risk of multiple complications. This article discusses the acute and long-term complications of ventricular assist devices.

show abstract

“…Other authors have addressed LVAD function, identified specific ICU concerns, and described LVAD devices 7–12 . The purposes of this review are to provide an overview of how one facility provides LVAD education for nurses, patients, families, and community health care providers and to identify new educational issues that have emerged as LVAD therapy is used in a broader patient base, including destination therapy.…”

mentioning

confidence: 99%

Nursing Education and Implications for Left Ventricular Assist Device Destination Therapy

Bond

Bolton

Nelson

2004

Progress Cardiovascular Nurs

View full text Add to dashboard Cite

The HeartMate VE Left Ventricular Assist Device (vented electric abdominally positioned pulsatile blood pump; Thoratec Corp., Pleasanton, CA), approved as a permanent support, or destination therapy, by the US Food and Drug Administration in 2002 and Medicare in 2003, is now a potential therapy for numerous patients. Postimplantation nursing care is crucial to the success of left ventricular support device therapy and long-term recipient outcome. Nurses also contribute to cost containment, making this a viable treatment for the facility and the patient. Consequently, nurses must be educated about left ventricular assist device concepts and challenges, the benefits of device placement, intensive care unit and postintensive care unit daily care requirements, and outpatient preparation. This knowledge will enable nurses to provide necessary care and to educate recipients, families, and community health care providers on how to give appropriate posthospital care.

show abstract

Current and Potential Applications of Left Ventricular Assist Devices

Cited by 11 publications

References 3 publications

Computational analysis of the effect of the type of LVAD flow on coronary perfusion and ventricular afterload

Computational analysis of the effect of the type of LVAD flow on coronary perfusion and ventricular afterload

Complications in Patients With Ventricular Assist Devices

Nursing Education and Implications for Left Ventricular Assist Device Destination Therapy

Contact Info

Product

Resources

About